TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9869669

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (3 cycles of cisplatin and fluorouracil, followed by 2 additional cycles after surgery)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Immediate surgery (surgery alone)
Number of subjects: 440
Study: 7613890

Group type: EXPERIMENTAL
Intervention: Metronidazole 500 mg intravenously 2 h before surgery
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Metronidazole during induction of anaesthesia
Number of subjects: 26
Study: 2529072

Group type: EXPERIMENTAL
Intervention: Epidural sufentanil 30, 50, or 75 micrograms per dose in 20 ml normal saline solution
Number of subjects: 22
Study: 27633

Group type: EXPERIMENTAL
Intervention: Prochlorperazine edisylate 10mg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Hydroxyzine hydrochloride 100mg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 61
Study: 30460598

Group type: EXPERIMENTAL
Intervention: SBP 140-160 mmHg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SBP 161-180 mmHg
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: SBP 181-200 mmHg
Number of subjects: 218
Study: 29181517

Group type: EXPERIMENTAL
Intervention: Surgical simulation session using the Eyesi Cataract Surgery Simulator (VRmagic) for 2 hours
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control session for 2 hours (passive and active tasks)
Number of subjects: 8
Study: 24735840

Group type: EXPERIMENTAL
Intervention: Ultrasound tissue characterisation (UTC) imaging on day 0, day 1, day 2, and day 4 postgame
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ultrasound tissue characterisation (UTC) imaging
Number of subjects: 18
Study: 24154513

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol 250/50 µg, twice daily
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 µg, twice daily
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 21483463

Group type: EXPERIMENTAL
Intervention: Educational booklet
Number of subjects: 436

Group type: COMPARATOR
Intervention: Usual instructions (Control)
Number of subjects: 436
Study: 19394976

Group type: EXPERIMENTAL
Intervention: pioglitazone + metformin
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: glimepiride + metformin
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: pioglitazone alone
Number of subjects: 271

Group type: COMPARATOR
Intervention: metformin alone
Number of subjects: 271
Study: 17537217

Group type: EXPERIMENTAL
Intervention: extraperitoneal laparoscopic radical prostatectomy (eLRP)
Number of subjects: 403

Group type: COMPARATOR
Intervention: open retropubic radical prostatectomy (RRP)
Number of subjects: 403
Study: 15151693

Group type: EXPERIMENTAL
Intervention: Basic information with details of the expected recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic information with details of both the operative procedures and recovery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Basic information with details of the operative procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic information only
Number of subjects: 0
Study: 10928463

Group type: EXPERIMENTAL
Intervention: Desogestrel-containing OC (150 microg desogestrel/30 microg ethinylestradiol)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-containing OC (150 microg levonorgestrel/30 microg ethinylestradiol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of desogestrel vs levonorgestrel
Number of subjects: 28
Study: 9483810

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (0.03 mg) plus dienogest (2 mg)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dienogest alone (0.5-2 mg/day)
Number of subjects: 4

Group type: COMPARATOR
Intervention: EE/DNG
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Sequential regimen of dienogest, chlormadinone acetate, and desogestrel
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Norethindrone acetate and levonorgestrel
Number of subjects: 4
Study: 8141827

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA, mesalazine) 500 mg tid in slow release tablets (Salofalk)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 5-aminosalicylic acid (5-ASA, mesalazine) 250 mg in slow release tablets (Salofalk)
Number of subjects: 18
Study: 3707796

Group type: EXPERIMENTAL
Intervention: Morphine 2 mg with adrenaline 50 micrograms
Number of subjects: 14

Group type: COMPARATOR
Intervention: Morphine 2 mg without adrenaline (plain morphine)
Number of subjects: 14
Study: 30782172

Group type: EXPERIMENTAL
Intervention: Placebo (informed that the capsule contained caffeine)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (no substance)
Number of subjects: 4
Study: 29157808

Group type: EXPERIMENTAL
Intervention: Saffron (15 mg/Bid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25444531

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (10^8 colony-forming units)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23181634

Group type: EXPERIMENTAL
Intervention: Awake SBP/DBP means ≥130/75 mm Hg
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: Asleep SBP/DBP means ≥110/65 mm Hg
Number of subjects: 3344

Group type: COMPARATOR
Intervention: Awake SBP/DBP means 135/85 mm Hg
Number of subjects: 3344

Group type: COMPARATOR
Intervention: Asleep SBP/DBP means 120/70 mm Hg
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: Awake SBP/DBP means 120/75 mm Hg
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: Asleep SBP/DBP means 105/60 mm Hg
Number of subjects: 3344

Group type: EXPERIMENTAL
Intervention: Ambulatory SBP/DBP thresholds 15/10 mm Hg lower for patients with diabetes than without diabetes
Number of subjects: 3344
Study: 21704300

Group type: EXPERIMENTAL
Intervention: Preoperative β‐blockers
Number of subjects: 12855

Group type: COMPARATOR
Intervention: No preoperative β‐blockers
Number of subjects: 12855
Study: 19023879

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 10
Study: 16838611

Group type: EXPERIMENTAL
Intervention: KTP-Laser treatment
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Combined treatment (KTP-Laser + low-pressure TURP)
Number of subjects: 151
Study: 12883779

Group type: EXPERIMENTAL
Intervention: Antiresorptive and osteoanabolic drugs for osteoporosis treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment instituted during hospitalisation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continued treatment monitored by family doctor
Number of subjects: 0
Study: 11253344

Group type: EXPERIMENTAL
Intervention: High fixed doses of unfractionated heparin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Low doses of unfractionated heparin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nonsteroidal anti-inflammatory agents
Number of subjects: 21
Study: 8750460

Group type: EXPERIMENTAL
Intervention: Quality-of-life (QOL) end points in oncology clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality-of-life (QOL) instruments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis plan for QOL
Number of subjects: 0
Study: 1320907

Group type: EXPERIMENTAL
Intervention: Intravenous granisetron (40 micrograms/kg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Alizapride (4 mg/kg followed by 4 mg/kg at 4 and 8 h post-treatment) plus dexamethasone (8 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Alizapride plus dexamethasone
Number of subjects: 200
Study: 6338383

Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 30972405

Group type: EXPERIMENTAL
Intervention: Infant Program intervention, a universally delivered service aimed at promoting healthy behaviours and reducing obesity risk in infants.
Number of subjects: 0
Study: 29855986

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761® (120 mg, twice a day)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Pentoxifylline (600 mg, twice a day)
Number of subjects: 197
Study: 26455794

Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 40
Study: 24585444

Group type: EXPERIMENTAL
Intervention: Single dose of green tea (200 mL of 1.5%, w/v)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Regular intake of green tea (2 × 200 mL 1%, w/v per day for 7 days)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Single dose of green tea
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Regular intake of green tea
Number of subjects: 16
Study: 21745654

Group type: EXPERIMENTAL
Intervention: Office training group (personal ergonomic training and workstation adjustments)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Photo-training group (office training + automatic frequent-feedback system with posture photos)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 20808589

Group type: EXPERIMENTAL
Intervention: Immediate physical therapy group (n = 16)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Delayed physical therapy group (n = 15)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study: 17667480

Group type: EXPERIMENTAL
Intervention: Newly medicated
Number of subjects: 370

Group type: COMPARATOR
Intervention: Not medicated
Number of subjects: 370
Study: 16103667

Group type: EXPERIMENTAL
Intervention: Granisetron + Alprazolam (G+A)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Granisetron alone (G)
Number of subjects: 19
Study: 12186662

Group type: EXPERIMENTAL
Intervention: Diet history interviews and three‐day weighed food records administered at one‐month intervals in trial 1
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Diet history interviews and three‐day weighed food records administered at three‐month intervals in trial 2
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 91
Study: 10195338

Group type: EXPERIMENTAL
Intervention: Medicated with neuroleptics
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Unmedicated schizophrenic patients
Number of subjects: 59

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 59
Study: 7757355

Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) measurements in patients with pulmonary cancer and other diseases
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Neuron-specific enolase (NSE) measurements in pregnant patients
Number of subjects: 10

Group type: COMPARATOR
Intervention: Neuron-specific enolase (NSE) measurements in healthy controls
Number of subjects: 10
Study: 1430700

Group type: EXPERIMENTAL
Intervention: Statis extracts
Number of subjects: 3
Study: 6376235

Group type: EXPERIMENTAL
Intervention: 10 mg Trestatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 20 mg Trestatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 50 mg Trestatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 100 mg Trestatin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 10 mg Trestatin (diabetic patients)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 30 mg Trestatin (diabetic patients)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (normal subjects)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (diabetic patients)
Number of subjects: 13
Study: 30741623

Group type: EXPERIMENTAL
Intervention: Edaravone therapy
Number of subjects: 11508

Group type: COMPARATOR
Intervention: Control (no edaravone therapy)
Number of subjects: 11508
Study: 30244190

Group type: EXPERIMENTAL
Intervention: Immediate invasive coronary strategy in conscious OHCA survivors
Number of subjects: 86

Group type: COMPARATOR
Intervention: Primary PCI in STEMI patients without OHCA
Number of subjects: 86
Study: 26598090

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg 3 times/day
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 23491928

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous SAMe treatment (1,000mg for seven days)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (standardized treatment)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous SAMe treatment
Number of subjects: 79
Study: 21652619

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (800/100 mg once daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Darunavir/ritonavir plus two nucleoside analogues
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 256
Study: 20002740

Group type: EXPERIMENTAL
Intervention: Xeomin® treatment
Number of subjects: 100
Study: 16440533

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 88 microg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 220 microg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 440 microg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate hydrofluoroalkane inhalation aerosol (all doses)
Number of subjects: 0
Study: 14763718

Group type: EXPERIMENTAL
Intervention: Community stroke team rehabilitation
Number of subjects: 421

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 421
Study: 11386892

Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (60 mg daily)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study: 9362431

Group type: EXPERIMENTAL
Intervention: Chemotherapy (standard combination regimens such as cyclophosphamide, methotrexate, and 5-fluorouracil; cyclophosphamide, doxorubicin, and 5-fluorouracil; mitoxantrone and 5-FU; single agents including paclitaxel and docetaxel)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Hormonal therapy (aminoglutethimide, medroxyprogesterone acetate, tamoxifen, newer aromatase inhibitors such as anastrozole, fadrozole, and letrozole, megestrol acetate)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 195
Study: 1382676

Group type: EXPERIMENTAL
Intervention: 10 mg of zolpidem (Stilnox)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Delayed bedtime (3 a.m.)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (2 nights)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 4054135

Group type: EXPERIMENTAL
Intervention: Rehabilitation (R) group
Number of subjects: 167

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 167
Study: 31260833

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 3382

Group type: COMPARATOR
Intervention: Chest radiography (CXR)
Number of subjects: 3382

Group type: EXPERIMENTAL
Intervention: Overall mortality with LDCT
Number of subjects: 3382

Group type: COMPARATOR
Intervention: Overall mortality with CXR
Number of subjects: 3382
Study: 29530371

Group type: EXPERIMENTAL
Intervention: Poor Sleepers (upper quartile on CSHQ‐ASD)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Good Sleepers (lower quartile on CSHQ‐ASD)
Number of subjects: 177
Study: 25940151

Group type: EXPERIMENTAL
Intervention: PPI therapy for 5 weeks after endoscopic resection (ER)
Number of subjects: 229
Study: 25157724

Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 101
Study: 22681603

Group type: EXPERIMENTAL
Intervention: Blood flow restriction (BFR) with elastic knee wraps (KW) during leg extensions at 30% 1RM until failure
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (CON) group without blood flow restriction
Number of subjects: 13
Study: 20454491

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 205

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (working patients)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Extracapsular cataract extraction (working patients)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Phacoemulsification vs Extracapsular cataract extraction
Number of subjects: 205
Study: 18586835

Group type: EXPERIMENTAL
Intervention: FLGTN-HUT (800 mcg, metred spray)
Number of subjects: 149

Group type: COMPARATOR
Intervention: HUT (standard 40-min passive tilt)
Number of subjects: 149
Study: 16133387

Group type: EXPERIMENTAL
Intervention: CT correction
Number of subjects: 122

Group type: COMPARATOR
Intervention: Cs correction
Number of subjects: 122
Study: 11844897

Group type: EXPERIMENTAL
Intervention: Zolmitriptan 2.5 mg
Number of subjects: 666

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 900 mg and metoclopramide 10 mg
Number of subjects: 666
Study: 10417049

Group type: EXPERIMENTAL
Intervention: IFN‐alpha2B (5.0 MU three times a week for 1 year)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Not applicable (control group did not receive IFN)
Number of subjects: 96
Study: 7588672

Group type: EXPERIMENTAL
Intervention: 0.05 micrograms kg‐1 min‐1 of PGE1
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 0.1 microgram kg‐1 min‐1 of PGE1
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 45
Study: 2314351

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of prostaglandin E1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial infusion of buflomedil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control conditions (no infusion)
Number of subjects: 0
Study: 476231

Group type: EXPERIMENTAL
Intervention: Dopamine-beta-hydroxylase inhibitor (fusaric acid) combined with L-dopa (500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: L-dopa alone
Number of subjects: 0
Study: 30883052

Group type: EXPERIMENTAL
Intervention: Centrifugal-flow pump
Number of subjects: 1028

Group type: COMPARATOR
Intervention: Axial-flow pump
Number of subjects: 1028
Study: 29190761

Group type: EXPERIMENTAL
Intervention: 2 minutes standing every 20 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 2 minutes walking every hour
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 10 minutes standing every hour
Number of subjects: 10

Group type: COMPARATOR
Intervention: Prolonged sitting control condition
Number of subjects: 10
Study: 25602889

Group type: EXPERIMENTAL
Intervention: HIVSRR plus savings-led microfinance intervention (n=57)
Number of subjects: 107

Group type: COMPARATOR
Intervention: HIVSRR alone (n=50)
Number of subjects: 107
Study: 23948862

Group type: EXPERIMENTAL
Intervention: Higher RBC levels of total n‐3 LC‐PUFA and DHA in patients who developed POAF
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Postoperative interleukin‐6 levels
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Inflammatory mediators
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: n‐3 LC‐PUFA levels in RBC membranes measured prior to CABG and on postoperative day 3
Number of subjects: 125
Study: 21208928

Group type: EXPERIMENTAL
Intervention: Maternal tuberculosis (TB) during pregnancy and up to 12 months after delivery
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Maternal TB
Number of subjects: 783
Study: 19412843

Group type: EXPERIMENTAL
Intervention: Morning irradiation (08:00-11:00 h)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Evening irradiation (15:00-18:00 h)
Number of subjects: 212
Study: 17291359

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15562885

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily for 4 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cetirizine hydrochloride (10 mg daily for 4 days)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of Loratadine vs Cetirizine hydrochloride
Number of subjects: 18
Study: 11213011

Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy via culdotomy (Group B)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Vaginal cystectomy without laparoscopy (Group A)
Number of subjects: 79
Study: 9669460

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (no active treatment)
Number of subjects: 21
Study: 7804490

Group type: EXPERIMENTAL
Intervention: Physician-initiated discussion on advance directives (AD)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Physician-initiated discussion on health promotion issues
Number of subjects: 100
Study: 3044872

Group type: COMPARATOR
Intervention: Codergocrine mesylate, increasing dosage over 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 29634641

Group type: EXPERIMENTAL
Intervention: Medium difficulty level
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hard difficulty level
Number of subjects: 36

Group type: COMPARATOR
Intervention: Low difficulty level
Number of subjects: 36
Study: 28605603

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 7637

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 7637
Study: 25088249

Group type: EXPERIMENTAL
Intervention: Three-dimensional conformal radiotherapy followed by 2-3 series of TACE (Group A)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolisation (TACE) alone (Group B)
Number of subjects: 63
Study: 25125055

Group type: EXPERIMENTAL
Intervention: Rop/Dx (ropivacaine with dexamethasone)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Rop (ropivacaine alone)
Number of subjects: 80
Study: 19815346

Group type: EXPERIMENTAL
Intervention: Task persistence
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 241
Study: 18311126

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control
Number of subjects: 9
Study: 16153780

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (1000mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 12816696

Group type: EXPERIMENTAL
Intervention: OAC triple therapy
Number of subjects: 552

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552